Table 1.
Supraoptic nucleus oxytocin | Supraoptic nucleus pSTAT5 | Paraventricular nucleus oxytocin | Paraventricular nucleus pSTAT5 | |
---|---|---|---|---|
Dioestrus + vehicle | 55 ± 2 (n = 5) | 0 ± 0 (n = 5) | 100 ± 4 (n = 5) | 0 ± 0 (n = 5) |
Lactating + vehicle | 56 ± 2 (n = 5) | 0 ± 0 (n = 5) | 96 ± 7 (n = 4) | 0 ± 0 (n = 4) |
Dioestrus + prolactin | 58 ± 2 (n = 7) | 67 ± 4 (n = 7) | 107 ± 8 (n = 7) | 154 ± 12 (n = 7) |
Lactating + prolactin | 67 ± 4 (n = 6) | 65 ± 6 (n = 6) | 123 ± 9 (n = 6) | 143 ± 25 (n = 6) |
Main effect of status | F 1,22 = 2.92 | F 1,22 = 0.06 | F 1,21 = 0.48 | F 1,21 = 0.11 |
P = 0.10 | P = 0.81 | P = 0.50 | P = 0.75 | |
Main effect of prolactin | F 1,22 = 4.81 | F 1,22 = 255.04 | F 1,21 = 3.76 | F 1,21 = 71.32 |
P = 0.04 | P < 0.001 | P = 0.07 | P < 0.001 | |
Interaction | F 1,22 = 1.50 | F 1,22 = 0.06 | F 1,21 = 1.3 | F 1,21 = 0.11 |
P = 0.24 | P = 0.81 | P = 0.27 | P = 0.75 |
Data shown are the mean number (±SEM) of oxytocin‐positive neurones and pSTAT5‐positive neurones per section in the supraoptic and paraventricular nuclei after 500 ng i.c.v. prolactin after three 500 μg s.c. bromocriptine injections 28–4 h beforehand. Significant P‐values are in bold.